Diabetes, obesity & metabolism · 2025
Initiation of sodium-glucose cotransporter-2 inhibitors and the risk of infection-related hospitalisations: A population-based cohort study.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Alfonso Arvez Maria J, Tan George S Q, Ademi Zanfina, Ilomäki Jenni, Bell J Simon
Аннотация
AIMS: To assess the association between initiating sodium-glucose cotransporter-2 (SGLT2) inhibitors compared to dipeptidyl peptidase-4 (DPP4) inhibitors and the rate of infection-related hospitalisations among individuals with type 2 diabetes following hospital discharge.
MATERIALS AND METHODS: In this active comparator, new user cohort study, we compared rates of infection-related hospitalisations among new users of SGLT2 inhibitors to new users of DPP4 inhibitors over 2 years post-discharge. We analysed data from all public and private hospitals in Victoria, Australia. Weighted incidence rate ratios (wIRRs) and 95% CIs were estimated using negative binomial regression with inverse probability of treatment weighting.
RESULTS: New users of SGLT2 inhibitors had a lower rate of overall infection-related hospitalisations (wIRR 0.74, 95% CI 0.71-0.77), and specifically for sepsis (wIRR 0.60, 95% CI 0.54-0.66), pneumonia (wIRR 0.61, 95% CI 0.55-0.66), gastrointestinal infections (wIRR 0.77, 95% CI 0.70-0.85), urinary tract infections (wIRR 0.38, 95% CI 0.34-0.43), respiratory tract infections (wIRR 0.68, 95% CI 0.63-0.74), influenza (wIRR 0.63, 95% CI 0.48-0.83) and kidney infections (wIRR 0.49, 95% CI 0.34-0.71). No significant differences were observed for rates of hospitalisation for cellulitis (wIRR 1.04, 95% CI 0.98-1.10). In contrast, hospitalisations for osteomyelitis (wIRR 1.14, 95% CI 1.02-1.27), foot infections (wIRR 1.25, 95% CI 1.19-1.31), and genital mycotic infections (wIRR 1.48, 95% CI 1.24-1.76) were higher in new users of SGLT2 inhibitors.
CONCLUSIONS: Initiating SGLT2 inhibitors is associated with lower overall rates of infection-related hospitalisations over 2 years. However, the association between SGLT2 inhibitors and infection-related hospitalisations is dependent on the type of infection.
MATERIALS AND METHODS: In this active comparator, new user cohort study, we compared rates of infection-related hospitalisations among new users of SGLT2 inhibitors to new users of DPP4 inhibitors over 2 years post-discharge. We analysed data from all public and private hospitals in Victoria, Australia. Weighted incidence rate ratios (wIRRs) and 95% CIs were estimated using negative binomial regression with inverse probability of treatment weighting.
RESULTS: New users of SGLT2 inhibitors had a lower rate of overall infection-related hospitalisations (wIRR 0.74, 95% CI 0.71-0.77), and specifically for sepsis (wIRR 0.60, 95% CI 0.54-0.66), pneumonia (wIRR 0.61, 95% CI 0.55-0.66), gastrointestinal infections (wIRR 0.77, 95% CI 0.70-0.85), urinary tract infections (wIRR 0.38, 95% CI 0.34-0.43), respiratory tract infections (wIRR 0.68, 95% CI 0.63-0.74), influenza (wIRR 0.63, 95% CI 0.48-0.83) and kidney infections (wIRR 0.49, 95% CI 0.34-0.71). No significant differences were observed for rates of hospitalisation for cellulitis (wIRR 1.04, 95% CI 0.98-1.10). In contrast, hospitalisations for osteomyelitis (wIRR 1.14, 95% CI 1.02-1.27), foot infections (wIRR 1.25, 95% CI 1.19-1.31), and genital mycotic infections (wIRR 1.48, 95% CI 1.24-1.76) were higher in new users of SGLT2 inhibitors.
CONCLUSIONS: Initiating SGLT2 inhibitors is associated with lower overall rates of infection-related hospitalisations over 2 years. However, the association between SGLT2 inhibitors and infection-related hospitalisations is dependent on the type of infection.